BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15653447)

  • 1. Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport.
    Abellan R; Ventura R; Pichini S; Pascual JA; Pacifici R; Di Carlo S; Bacosi A; Segura J; Zuccaro P
    Clin Chem Lab Med; 2005; 43(1):75-85. PubMed ID: 15653447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes.
    Abellan R; Ventura R; Palmi I; di Carlo S; Bacosi A; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
    J Pharm Biomed Anal; 2008 Nov; 48(3):844-52. PubMed ID: 18617352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Cowan DA; Bassett EE; Stow M; Sönksen PH; Holt RI
    Drug Test Anal; 2012 Jun; 4(6):455-9. PubMed ID: 22511534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
    Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker detection of rhGH doping: an excretion study.
    Jing J; Zhou X; He C; Zhang L; Yang S; Xu Y; Xie M; Yan Y; Su H; Wu M
    Drug Test Anal; 2012 Oct; 4(10):739-44. PubMed ID: 23074170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant growth hormone misuse: insulin-like growth factor I and procollagen type III peptide.
    Abellan R; Ventura R; Pichini S; Di Giovannandrea R; Bellver M; Olive R; Pacifici R; Pascual JA; Zuccaro P; Segura J
    Int J Sports Med; 2006 Dec; 27(12):976-83. PubMed ID: 16612742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immunoassays for the measurement of insulin and C-peptide as indirect biomarkers of insulin misuse in sport: values in selected population of athletes.
    Abellan R; Ventura R; Palmi I; di Carlo S; di Giovannandrea R; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
    J Pharm Biomed Anal; 2009 Apr; 49(3):793-9. PubMed ID: 19181472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.
    Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of physical fitness and endurance exercise on indirect biomarkers of growth hormone and insulin misuse: Immunoassay-based measurement in urine samples.
    Pichini S; Ventura R; Palmi I; di Carlo S; Bacosi A; Langohr K; Abellan R; Pascual JA; Pacifici R; Segura J; Zuccaro P
    J Pharm Biomed Anal; 2010 Dec; 53(4):1003-10. PubMed ID: 20674210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracking growth hormone abuse in sport: performance of marker proteins in a controlled setting.
    Bosch J; Such-Sanmartín G; Segura J; Gutiérrez-Gallego R
    Anal Chim Acta; 2012 Oct; 745():118-23. PubMed ID: 22938615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of immunoassays for the measurement of erythropoietin (EPO) as an indirect biomarker of recombinant human EPO misuse in sport.
    Abellan R; Ventura R; Pichini S; Remacha AF; Pascual JA; Pacifici R; Di Giovannandrea R; Zuccaro P; Segura J
    J Pharm Biomed Anal; 2004 Sep; 35(5):1169-77. PubMed ID: 15336362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory issues in the implementation of the marker method.
    Cowan DA; Bartlett C
    Growth Horm IGF Res; 2009 Aug; 19(4):357-60. PubMed ID: 19574074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
    Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of immunoassays for the measurement of soluble transferrin receptor as an indirect biomarker of recombinant human erythropoietin misuse in sport.
    Abellan R; Ventura R; Pichini S; Sarda MP; Remacha AF; Pascual JA; Palmi I; Bacosi A; Pacifici R; Zuccaro P; Segura J
    J Immunol Methods; 2004 Dec; 295(1-2):89-99. PubMed ID: 15627614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.
    Di Luigi L; Rigamonti AE; Agosti F; Mencarelli M; Sgrò P; Marazzi N; Cella SG; Müller EE; Sartorio A
    Eur J Endocrinol; 2009 May; 160(5):753-8. PubMed ID: 19258430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
    Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
    Kniess A; Ziegler E; Thieme D; Müller RK
    J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-validation of commercial enzyme-linked immunosorbent assay and radioimmunoassay for porcine C-peptide concentration measurements in non-human primate serum.
    Gresch SC; Mutch LA; Janecek JL; Hegstad-Davies RL; Graham ML
    Xenotransplantation; 2017 Sep; 24(5):. PubMed ID: 28731212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
    Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.